Ratings Sanofi

Equities

Market Closed - Euronext Paris Other stock markets 16:55:00 08/07/2025 BST			Pre-market 06:51:00
83.33 ^EUR	+1.08%		82.84	-0.59%

07-08	SANOFI : UBS maintains a Buy rating	ZD
07-03	SANOFI : Goldman Sachs reiterates its Neutral rating	ZD

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
According to MSCI, the company's ESG score for its industry is good.

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
This company will be of major interest to investors in search of a high dividend stock.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The company's earnings releases usually do not meet expectations.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	SANOFI				119B
	ELI LILLY AND COMPANY				698B
	JOHNSON & JOHNSON				375B
	ABBVIE INC.				335B
	NOVO NORDISK A/S				313B
	ROCHE HOLDING AG				259B
	NOVARTIS AG				240B
	ASTRAZENECA PLC				217B
	MERCK & CO., INC.				204B
	AMGEN INC.				160B
	Average				292.12B
	Weighted average by Cap.